| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01136941 | Sickle Cell Disease | Drug: Zileuton | Children's Hospital Medical Center, Cincinnati | Phase 1 | 2010-09-01 | 2014-06-17 |
| NCT01130688 | Chronic Myelogenous Leukemia | Drug: Zileuton | University of Massachusetts, Worcester | Phase 1 | 2010-01-01 | 2015-05-26 |
| NCT02047149 | Chronic Myelogenous Leukemia | Drug: Zileuton (Zyflo庐) Dasatinib (Sprycel庐)|Drug: Dosing with Zileuton/Dasatinib in CML|Drug: Daily dosing of Zileuton/Dasatinib|Drug: Daily dosing with Zileuton/Dasatinib for CML | University of Massachusetts, Worcester|Bristol-Myers Squibb | Phase 1 | 2014-01-01 | 2016-09-29 |
| NCT00575861 | Asthma | Drug: zileuton | Gelb, Arthur F., M.D. | Phase 4 | 2005-09-01 | 2007-12-18 |
| NCT00486343 | Asthma | Drug: Zileuton CR|Drug: Placebo | Critical Therapeutics | Phase 4 | 2007-07-01 | 2008-04-01 |
| NCT02348203 | Pulmonary Nodules|Tobacco Use Disorder | Drug: Aspirin|Other: Laboratory Biomarker Analysis|Other: Placebo|Other: Placebo|Drug: Zileuton | National Cancer Institute (NCI) | Phase 2 | 2016-01-01 | 2017-01-31 |
| NCT00262405 | Idiopathic Pulmonary Fibrosis | Drug: zileuton|Drug: azathioprine/prednisone | University of Michigan|National Institutes of Health (NIH) | Phase 2 | 2001-01-01 | 2015-12-02 |
| NCT00534625 | Asthma | Drug: zileuton|Drug: placebo|Drug: zileuton | Critical Therapeutics | Phase 2 | 2007-09-01 | 2008-03-19 |
| NCT00493974 | Pulmonary Disease, Chronic Obstructive | Drug: Zileuton|Drug: Placebo | University of Minnesota - Clinical and Translational Science Institute|National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 2007-03-01 | 2016-08-24 |
| NCT00056004 | Head and Neck Cancer|Lung Cancer | Drug: zileuton | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) | Phase 2 | 2003-06-01 | 2013-04-25 |
| NCT01021215 | Tobacco Use Disorder | Drug: Zileuton|Drug: Celecoxib|Other: laboratory biomarker analysis | National Cancer Institute (NCI) | Phase 1|Phase 2 | 2010-05-01 | 2015-04-01 |
| NCT00098358 | Acne Vulgaris | Drug: Zileuton | Critical Therapeutics | Phase 2 | 2004-11-01 | 2007-02-05 |
| NCT00299065 | Asthma | Drug: Zileuton injection | Critical Therapeutics | Phase 1|Phase 2 | 2006-01-01 | 2007-09-24 |
| NCT01805687 | Asthma | Drug: Zileuton extended release | Cornerstone Therapeutics Inc. | Phase 4 | 2013-03-01 | 2014-08-22 |
| NCT00070486 | Lung Cancer | Drug: carboplatin|Drug: celecoxib|Drug: gemcitabine hydrochloride|Drug: zileuton | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Phase 2 | 2003-12-01 | 2016-06-28 |
| NCT01174056 | Lung Inflammation | Drug: Zileuton|Drug: Pioglitazone placebo|Drug: Zileuton placebo|Drug: Pioglitazone | Washington University School of Medicine|Doris Duke Charitable Foundation | Early Phase 1 | 2011-07-01 | 2014-04-22 |
| NCT00467831 | Hermansky-Pudlak Syndrome (HPS)|Pulmonary Fibrosis|Oculocutaneous Albinism|Platelet Storage Pool Deficiency|Metabolic Disease | Drug: Losartan|Drug: Zileuton|Drug: N-Acetylcysteine|Drug: Pravastatin|Drug: Erythromycin | National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC) | Phase 1|Phase 2 | 2007-04-01 | 2013-06-03 |
| NCT00723021 | Asthma | Drug: PF-04191834|Drug: PF-04191834|Drug: PF-04191834|Drug: zileuton|Drug: Placebo | Pfizer | Phase 2 | 2008-07-01 | 2012-12-27 |
| NCT01125748 | Allergic Asthma | Drug: Omalizumab|Drug: Placebo|Drug: Asthma therapies | Genentech, Inc. | Phase 4 | 2010-05-01 | 2014-10-08 |
| NCT00595114 | Asthma|Pulmonary Disease, Chronic Obstructive | Brigham and Women's Hospital|National Heart, Lung, and Blood Institute (NHLBI) | Early Phase 1 | 2007-12-01 | 2016-09-04 |
